CFDE Data Portal | Search BBS7-DT

	Label	Description
	BBS7-DT Gene (Entity type)	ENSG00000261501 - BBS7 divergent transcript
	GSE135350 3 V 5 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 11 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 10 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE189859 GSE189861 IDH1 knockout 4 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE201309 5 V 0 MATRINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE153867 olaparib 6 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 5 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE206931 WDR5 inhibition WIN 3 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE207499 sphingosine 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS

BBS7-DT

ENSG00000261501 - BBS7 divergent transcript

GSE135350 3 V 5 DEXAMETHASONE HUMAN UP

A Gene Set from LINCS

GSE216043 cisplatin 11 v 2 human dn

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 10 v 7 human dn

A Gene Set from LINCS

GSE189859 GSE189861 IDH1 knockout 4 v 2 human dn

A Gene Set from LINCS

GSE201309 5 V 0 MATRINE HUMAN UP

A Gene Set from LINCS

GSE153867 olaparib 6 v 4 human dn

A Gene Set from LINCS

GSE146358 dopamine 5 v 2 human up

A Gene Set from LINCS

GSE206931 WDR5 inhibition WIN 3 v 6 human up

A Gene Set from LINCS

GSE207499 sphingosine 1 v 0 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.